Last updated: October 29, 2026
TENIVAC is Sanofi Pasteur’s tetanus and diphtheria toxoids adsorbed vaccine for adults and children aged 7 years and older. Its market is mature, low-growth, and driven by routine booster vaccination, wound management, public-health procurement, and supply reliability rather than product differentiation. Sanofi does not disclose TENIVAC revenue separately, so its financial trajectory must be assessed through the broader Sanofi Vaccines business, U.S. vaccine demand, procurement patterns, and competitive supply.
What is TENIVAC and who manufactures it?
TENIVAC is a preservative-free, adsorbed Td vaccine containing tetanus toxoid and diphtheria toxoid. It is administered intramuscularly and is used for:
- Routine booster immunization against tetanus and diphtheria.
- Catch-up vaccination for individuals aged 7 years and older.
- Prophylaxis after wounds when tetanus immunization history is incomplete or uncertain.
- Booster vaccination when protection against pertussis is not required or when Td is selected under clinical guidance.
Sanofi Pasteur is the manufacturer and biologics license holder. The product is supplied in single-dose vials and syringes, subject to market-specific packaging and availability.
| Item |
TENIVAC profile |
| Active immunogens |
Tetanus toxoid and diphtheria toxoid |
| Drug class |
Combination bacterial toxoid vaccine |
| Dosage form |
Injectable suspension |
| Route |
Intramuscular |
| Primary population |
Adults and children aged 7 years and older |
| Manufacturer |
Sanofi Pasteur |
| U.S. regulatory pathway |
Biologics license |
| Commercial category |
Mature routine immunization product |
| Main alternatives |
TdVax, Tdap products, combination pediatric vaccines |
| U.S. market role |
Booster and wound-management vaccine |
The product competes with both direct Td vaccines and Tdap products. Tdap vaccines contain pertussis antigens and have displaced some Td use in routine adult booster schedules.
What is the FDA status of TENIVAC?
TENIVAC is FDA-approved and marketed as a licensed biological vaccine. The product is subject to biologics manufacturing, lot-release, labeling, pharmacovigilance, and postmarketing requirements applicable to vaccines.
The Centers for Disease Control and Prevention recommends Tdap for certain adolescent and adult vaccination uses, with Td or Tdap generally used for subsequent boosters and wound management depending on patient history and clinical circumstances. These recommendations influence the addressable market for TENIVAC because Tdap products can substitute for Td in several settings.
Key regulatory characteristics
| Regulatory factor |
Commercial effect |
| Licensed biological product |
Manufacturing and comparability requirements are substantial |
| Established clinical use |
Reduces adoption risk but limits premium pricing |
| Routine vaccine recommendations |
Supports recurring baseline demand |
| Tdap substitution |
Constrains long-term Td volume |
| Vaccine lot release and quality controls |
Increases supply-chain complexity |
| Public and institutional procurement |
Places pressure on price and margins |
TENIVAC is not a conventional small-molecule drug listed in the FDA Orange Book in the same way as tablets, capsules, or other generic medicines. Vaccine competition generally proceeds through separate biologics licensing and procurement channels rather than an Abbreviated New Drug Application and standard Orange Book Paragraph IV process.
When does TENIVAC lose exclusivity?
TENIVAC does not have a commercially meaningful, current patent exclusivity period comparable to a recently launched branded drug. The product was approved more than two decades ago, and its core composition and use are based on established tetanus and diphtheria toxoid technology.
No current blockbuster-style patent cliff is expected for TENIVAC. Market access is controlled by:
- Manufacturing know-how.
- Validated production processes.
- Regulatory compliance.
- Antigen sourcing and consistency.
- Adjuvant and formulation controls.
- Quality systems.
- Distribution contracts.
- Institutional purchasing relationships.
Patent and exclusivity assessment
| Protection category |
TENIVAC position |
| Core composition patent |
No commercially relevant unexpired core patent publicly identified |
| Use patents |
No material current method-of-use barrier identified |
| Formulation patents |
Historical vaccine formulation rights may exist, but no known blocking patent is central to current market access |
| Manufacturing patents |
Process know-how and regulatory validation remain more important than patent term |
| Regulatory exclusivity |
Historic approval-related exclusivity has expired |
| Orange Book listing |
Not a conventional Orange Book product |
| Biosimilar or interchangeable competition |
Not the primary competitive framework |
| Generic substitution |
No automatic generic substitution mechanism comparable to small molecules |
The practical moat is operational rather than patent-based. A new entrant would need to reproduce a reliable toxoid manufacturing process, demonstrate product quality and consistency, obtain a biologics license, and secure distribution and procurement access.
How many patents cover TENIVAC?
There is no publicly established count of active, blocking U.S. patents that materially protects TENIVAC as a commercial product. A search of historical vaccine-related patent families could identify patents covering toxoid production, detoxification, purification, adsorption, combination vaccines, containers, or delivery systems. Those families do not necessarily create current freedom-to-operate barriers.
Patent risk should therefore be separated into three categories:
- Product-specific patents directed to the marketed TENIVAC composition.
- Platform patents covering toxoid manufacture or adjuvant systems.
- Manufacturing and quality-control know-how that may be difficult to replicate but is not necessarily patent-protected.
For a mature Td vaccine, the second and third categories are more relevant than a traditional product patent estate. Trade secrets, process validation, historical batch data, supplier qualifications, and regulatory documentation can delay competition even when patent protection is weak.
What is the competitive landscape for TENIVAC?
TENIVAC competes in a declining or stable Td segment rather than a high-growth vaccine category. The main competitive pressures are Tdap substitution, public-sector purchasing, and the availability of alternative Td products.
Direct and indirect competitors
| Competitor category |
Examples |
Competitive impact |
| Direct Td vaccines |
TdVax and other licensed Td products |
Direct price and supply competition |
| Tdap vaccines |
Boostrix, Adacel |
Substitute for some booster indications |
| Pediatric combination vaccines |
DTaP-containing products |
Reduce demand for later standalone products |
| Public-sector vaccines |
Government-procured alternatives |
Increase price pressure |
| International-market products |
Locally licensed Td vaccines |
Fragment market access by country |
Boostrix, manufactured by GSK, and Adacel, manufactured by Sanofi Pasteur, are important indirect competitors. Tdap products have a broader antigen profile and can be preferred when pertussis protection is indicated. TENIVAC retains a role where Td is clinically appropriate, particularly in wound management and certain booster scenarios.
What market dynamics affect TENIVAC sales?
Routine booster demand
The adult Td market is supported by recurring booster recommendations, but vaccination timing is irregular. Demand depends on age, immunization history, healthcare access, occupational exposure, travel, and injury-related care.
Wound management
Emergency departments, urgent-care centers, primary-care offices, and occupational-health providers purchase Td vaccines for wound prophylaxis. This creates episodic demand that is less dependent on annual vaccination campaigns.
Tdap substitution
Tdap substitution is the largest structural pressure on TENIVAC. Tdap products can satisfy booster needs while adding pertussis protection. Expanded use of Tdap reduces the number of situations in which a provider selects Td specifically.
Public procurement
Government agencies, hospitals, pharmacies, and group purchasing organizations negotiate on price and supply. A mature vaccine product generally has limited pricing power unless it has a supply advantage or occupies a shortage-sensitive category.
Supply reliability
Vaccine production requires long lead times, specialized facilities, biological raw materials, testing, and lot release. A manufacturer with reliable supply can maintain share even without meaningful patent protection. Conversely, manufacturing interruptions can produce abrupt volume losses and create openings for competitors.
Pricing
TENIVAC is unlikely to support specialty-pharmaceutical pricing. Net pricing is influenced by:
- Federal and state purchasing.
- Hospital and clinic contracts.
- Pharmacy channel reimbursement.
- Distributor margins.
- Competitive bids.
- Product shortages.
- Package configuration.
The product’s value is primarily measured by volume, availability, and contract retention.
What is the financial trajectory of TENIVAC?
Sanofi does not report TENIVAC as a separate revenue line. The product is included within Sanofi’s broader Vaccines business, which also contains materially larger franchises such as influenza, meningococcal, pneumococcal, polio, pertussis, and travel vaccines.
This prevents a reliable standalone revenue or margin calculation. The financial trajectory is best characterized as follows:
| Period |
Expected TENIVAC financial profile |
| Historical launch and expansion |
Supported by establishment of a branded U.S. Td franchise |
| Mature period |
Stable but limited growth, with recurring booster and wound-care demand |
| Current period |
Volume constrained by Tdap substitution and mature-market pricing |
| Downside case |
Share loss from supply disruption, procurement exclusion, or Tdap conversion |
| Upside case |
Temporary volume gains during competitor shortages or public-health demand |
| Long-term profile |
Cash-generative mature product with limited standalone growth |
TENIVAC can remain economically useful even without high revenue growth. Manufacturing assets, regulatory infrastructure, and established distribution lower the incremental commercial cost of maintaining the product. The principal economic risk is not patent expiration. It is declining utilization combined with fixed quality and manufacturing costs.
Financial indicators to monitor
Because standalone TENIVAC sales are not disclosed, investors and licensing teams should monitor:
- Sanofi Vaccines segment revenue and operating income.
- Sanofi disclosures on vaccine volume, pricing, and supply.
- U.S. Td and Tdap procurement awards.
- CDC and federal contract pricing.
- Product availability and shortage notices.
- Sanofi manufacturing-capacity announcements.
- Competitor discontinuations or supply constraints.
- Changes in adult booster and wound-management recommendations.
- Public-sector immunization budgets.
- Pharmacy and institutional channel penetration.
What is the revenue exposure for Sanofi?
TENIVAC is unlikely to represent a material share of Sanofi’s total revenue. Sanofi’s financial exposure is concentrated in larger vaccine franchises and specialty-care products. The product’s strategic value is more likely to come from portfolio breadth, channel relationships, manufacturing utilization, and vaccine procurement access than from standalone sales concentration.
A TENIVAC disruption would probably have limited impact on consolidated Sanofi revenue but could affect:
- U.S. Td market share.
- Institutional customer relationships.
- Vaccine portfolio completeness.
- Production-network utilization.
- Short-term competitor capture.
- Sanofi’s ability to supply wound-management and booster channels.
The financial risk is asymmetric. TENIVAC has limited upside because the market is mature, while a prolonged shortage could cause disproportionate reputational and contractual effects in a narrow but operationally important category.
What generic launch risks exist for TENIVAC?
A conventional generic launch is not the relevant scenario. A competing Td vaccine would need to obtain its own regulatory authorization rather than rely on automatic pharmacy substitution.
Entry barriers
| Barrier |
Assessment |
| Patent protection |
Low to moderate |
| Clinical and regulatory burden |
High |
| Manufacturing complexity |
High |
| Need for validated toxoid process |
High |
| Procurement access |
Moderate to high |
| Brand loyalty |
Moderate in institutional channels |
| Pricing power |
Low |
| Supply reliability requirement |
High |
A new entrant could face fewer patent obstacles than a modern biologic, but the development program would still require significant time and capital. The entrant would need to demonstrate manufacturing consistency, potency, purity, sterility, safety, and acceptable immunogenicity under FDA requirements.
The most credible entry scenario is a licensed competing vaccine launched after a supply disruption, acquisition, manufacturing exit, or sustained procurement opportunity. A simple patent challenge is unlikely to be the main route.
Which companies are challenging TENIVAC?
No major public Paragraph IV litigation campaign against TENIVAC is central to the market. The product is not positioned like a small-molecule brand with multiple ANDA filers waiting for patent expiry.
Competitive threats instead come from:
- GSK through Boostrix.
- Sanofi’s own Adacel product, where Tdap use substitutes for Td.
- Existing Td vaccine manufacturers.
- Future biologics developers with validated toxoid platforms.
- Government or institutional procurement shifts.
The absence of high-profile patent litigation does not eliminate competition. It indicates that the commercial contest is based on regulatory authorization, supply, contracts, clinical recommendations, and pricing.
What formulation and manufacturing IP protects TENIVAC?
The principal technical barriers relate to the production and quality control of tetanus and diphtheria toxoids. Relevant know-how can include:
- Toxigenic bacterial culture.
- Toxin detoxification.
- Antigen purification.
- Adsorption to an aluminum-containing adjuvant.
- Combination and concentration control.
- Sterility assurance.
- Potency testing.
- Stability and container-closure validation.
- Batch consistency and release testing.
These controls are central to product quality but are not equivalent to an active patent monopoly. A competitor may be able to design around expired or narrow patents while still facing years of process development and regulatory validation.
What litigation and settlement risks affect TENIVAC?
No material public settlement agreement or active patent dispute is a primary determinant of TENIVAC’s commercial outlook. The more relevant disputes would involve:
- Supply contracts.
- Product liability.
- Manufacturing quality.
- Distribution agreements.
- Government procurement.
- Trademark or labeling matters.
- Alleged infringement involving manufacturing technology.
There is no established settlement-driven generic launch calendar for TENIVAC. Market entry timing would depend mainly on biologics development and FDA approval.
How does TENIVAC compare with Tdap vaccines?
| Attribute |
TENIVAC |
Tdap products |
| Antigens |
Tetanus and diphtheria |
Tetanus, diphtheria, and pertussis |
| Typical commercial role |
Td booster and wound management |
Adolescent, adult, pregnancy, and booster use |
| Market growth |
Mature or pressured |
Broader indication base |
| Substitution risk |
High from Tdap |
Lower, because of broader antigen coverage |
| Pricing position |
Generally mature-market |
Potentially stronger due to broader clinical utility |
| Main manufacturers |
Sanofi and other Td suppliers |
Sanofi, GSK |
| Regulatory framework |
Biologic vaccine |
Biologic vaccine |
| Patent dependence |
Low |
Product-specific estates may be more relevant, but mature products also face limited exclusivity |
TENIVAC remains relevant where a Td formulation is selected, but Tdap has greater strategic breadth. The competitive outlook therefore favors Tdap growth or stability over standalone Td expansion.
What is the geographic coverage of TENIVAC?
TENIVAC’s commercial importance is strongest in the United States, where Sanofi has established regulatory, distribution, and institutional relationships. International markets may use different Sanofi products, local brands, or national Td formulations under country-specific licenses.
Geographic risks include:
- Country-specific vaccine registration.
- Local procurement rules.
- Public-health tender cycles.
- National immunization schedules.
- Local manufacturing requirements.
- Currency and reimbursement exposure.
- Import and cold-chain controls.
A U.S. supply event may not translate directly into international revenue because product names, presentations, licenses, and procurement arrangements vary by jurisdiction.
Key Takeaways
- TENIVAC is a mature Sanofi Pasteur Td vaccine with recurring demand from booster vaccination and wound management.
- Its principal commercial threat is substitution by Tdap products, not patent expiry.
- No material current core patent or Orange Book exclusivity is central to the product’s market position.
- Competition requires a new biologics license, validated toxoid manufacturing, and procurement access.
- Sanofi does not disclose TENIVAC revenue separately.
- Standalone financial growth is likely limited, while supply reliability can materially affect short-term market share.
- The product is economically relevant as part of Sanofi’s vaccine portfolio but is unlikely to be a material driver of consolidated Sanofi revenue.
- The most likely competitive events are procurement changes, supply disruptions, Tdap substitution, and manufacturing exits rather than Paragraph IV litigation.
FAQs
Is TENIVAC a biologic drug or a vaccine?
TENIVAC is a licensed biological vaccine containing tetanus and diphtheria toxoids adsorbed to an adjuvant.
Is TENIVAC listed in the FDA Orange Book?
TENIVAC is not treated like a conventional small-molecule Orange Book product with ANDA-based generic substitution and Paragraph IV patent certification.
Does TENIVAC have biosimilar competition?
No conventional biosimilar competition is central to TENIVAC. Competing Td vaccines require separate regulatory authorization and are not automatically interchangeable under the standard biosimilar framework.
What could cause TENIVAC sales to decline?
The main causes would be greater Tdap use, reduced adult booster compliance, loss of institutional contracts, manufacturing interruption, competitor supply improvement, or a shift in clinical recommendations.
Could a competitor launch TENIVAC without infringing a patent?
Potentially, but regulatory and manufacturing barriers remain significant. A competitor would need its own licensed product, validated toxoid process, quality systems, and commercial distribution.
References
-
Centers for Disease Control and Prevention. (2024). Adult immunization schedule by age. U.S. Department of Health and Human Services.
-
Centers for Disease Control and Prevention. (2024). General best practice guidelines for immunization: Tetanus, diphtheria, and pertussis vaccination. U.S. Department of Health and Human Services.
-
Sanofi. (2024). Universal registration document and annual financial report 2023. Sanofi.
-
Sanofi Pasteur. (2023). TENIVAC: Tetanus and diphtheria toxoids adsorbed prescribing information. Sanofi Pasteur.
-
U.S. Food and Drug Administration. (2024). Vaccines licensed for use in the United States. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
